Textured breast implants for reconstruction may increase breast cancer recurrence: JAMA
Seoul, South Korea: The use of texture implants versus smooth implants after mastectomy for breast reconstruction appears to be associated with breast cancer recurrence, a recent study in the journal JAMA Surgery has found.Several concerns have been raised about the additional unexpected adverse effects of textured implants from the time studies have found a potential association between...
Seoul, South Korea: The use of texture implants versus smooth implants after mastectomy for breast reconstruction appears to be associated with breast cancer recurrence, a recent study in the journal JAMA Surgery has found.
Several concerns have been raised about the additional unexpected adverse effects of textured implants from the time studies have found a potential association between breast implant-related anaplastic large cell lymphoma (BIA-ALCL) and implant texture. In addition to the risk of BIA-ALCL development, breast cancer survivors also worry about whether the type of inserted implant increases the risk of cancer recurrence. A little evidence currently exists on the same.
Kyeong-Tae Lee, Sungkyunkwan University School of Medicine, Seoul, South Korea, and colleagues evaluated how the surface type of implants used for reconstruction affects the oncologic outcomes of breast cancer. Also, they identified the independent factors associated with the recurrence and survival of breast cancer including implant surface type.
The study was conducted at Samsung Medical Center in Seoul, South Korea. It included 650 patients (all women, with a mean [SD] age of 43.5 [7.4] years), representing 687 cases, recruited from a prospectively maintained database. Of the 687 cases, 274 (39.9%) received a smooth implant and 413 (60.1%) received a textured implant. They were followed up for at least 2 years after the insertion of the implant. Data analysis was performed from February 15, 2020, to March 5, 2020.
The main outcomes of interest were local and regional recurrence-free survival (LRRFS) and disease-free survival (DFS) rates. Cumulative incidence of oncologic events in the smooth implant and textured implant groups and their respective hazard ratios (HRs) were collected and updated regularly.
Key findings of the study include:
- Patients in these 2 surface texture groups had similar characteristics, including tumor staging (stage I: 37.2% vs 41.9%; stage II: 33.9% vs 28.8%; stage III: 5.1% vs 20 4.8%) and rates of adjuvant radiotherapy (15.3% vs 11.9%) and chemotherapy (41.2% vs 41.4%).
- The 5-year LRRFS was 96.7%, and the 5-year DFS was 95.2%.
- Compared with the use of a smooth implant, textured implant use was statistically significantly associated with lower DFS, and this difference remained significant after adjusting for estrogen receptor (ER) status and tumor stage (HR, 3.054).
- Similar statistically significant associations were observed on multivariable analysis of patients with ER-positive cancer (HR, 3.130) and those with invasive cancer (HR, 3.044).
- The association of textured implant use with recurrence (lower DFS) was more prominent in cases with late-stage (stage II or III) tumor (HR, 8.874).
- The LRRFS did not differ statistically significantly according to implant surface texture.
"The findings of this study suggest an association between the use of a textured implant in reconstruction and increased risk of breast cancer relapse, warranting the need for further investigation," concluded the authors.
The study, "Association of the Implant Surface Texture Used in Reconstruction With Breast Cancer Recurrence," is published in the journal JAMA Surgery.
DOI: https://jamanetwork.com/journals/jamasurgery/article-abstract/2771054
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd